Changes in the treatment of acute psychosis in a German Public Hospital from 1998 to 2004

Psychiatric Quarterly

Volumn 78, Issue 2, 2007, Pages 91-99

  Wessels, Tiemo ^a   Grünler, Dandy ^a   Bunk, Christa ^a   Specka, Michael ^a   Gastpar, Markus ^a   Scherbaum, Norbert ^a   Davids, Eugen ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Acute treatment strategies; Atypical antipsychotics; Schizophrenia; Switching antipsychotics

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; HYPNOTIC AGENT; MOOD STABILIZER;

ACUTE PSYCHOSIS; ADULT; ARTICLE; CATATONIC SCHIZOPHRENIA; CORRELATION ANALYSIS; FEMALE; GERMANY; HEBEPHRENIA; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PRESCRIPTION; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; COMMITMENT OF MENTALLY ILL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GERMANY; HOSPITALS, PUBLIC; HOSPITALS, UNIVERSITY; HUMANS; MALE; PRESCRIPTIONS, DRUG; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 34047135007     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-006-9030-y     Document Type: Article

References (30)

1. Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone, haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 346:16-22, 2002.
2. Emsley RA, Raniwalla J, Bailey PJ, et al: A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. International Clinical Psychopharmacology 15:121-131, 2000.
3. Gomez JC, Crawford AM: Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Journal of Clinical Psychiatry 62 (Suppl 2):6-11, 2001.
4. Kasper S, Lerman MN, McQuade RD, et al: Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology 6:325-337, 2003.
5. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Schizophrenia. 2006. Available at: www.psych.org/psych_pract/ treatg/pg/SchizPG-Complete-Feb04.pdf.
6. Gaebel W, Weinmann S, Sartorius N, et al: Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry 187:248-255, 2005.
7. De Hert M, van Eyck D, De Nayer A: Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. International Clinical Psychopharmacology 21 (Suppl 2):S11-S15, 2006.
8. Grohmann R, Engel RR, Geissler KH, et al: Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37 (Suppl 1):S27-S38, 2004.
9. Centorrino F, Goren JL, Hennen J, et al: Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. American Journal of Psychiatry 161:700-706, 2004.
10. Gaebel W, Riesbeck M, Janssen B, et al: Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions. European archives of psychiatry and clinical neuroscience 253:175-184, 2003.
11. Davids E, Bunk C, Specka M, et al: Psychotropic drug prescription in a psychiatric university hospital in Germany. Progress in neuro-psychopharmacology and bi ological psychiatry, 30 (6):1109-16, 2006.
12. Ganguly R, Kotzan JA, Miller LS, et al: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 65:1377-1388, 2004.
13. Centorrino F, Fogarty KV, Sani G, et al: Antipsychotic drug use: McLean Hospital, 2002. Human Psychopharmacology 20:355-358, 2005.
14. Weinmann S, Janssen B, Gaebel W: Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. Journal of Clinical Psychiatry 65:1099-1105, 2004.
15. Covell NH, Jackson CT, Evans AC, et al: Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophrenia Bulletin 28:17-29, 2002.
16. Rittmannsberger H, Meise U, Schauflinger K, et al: Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur opean Psychiatry 14:33-40, 1999.
17. Ananth J, Parameswaran S, Gunatilake S: Antipsychotic polypharmacy. Current Pharmaceutical design 10:2231-2238, 2004.
18. Schussler G, Muller-Oerlinghausen B: Polypharmacy in psychiatric practice. Comprehensive Psychiatry 25:566-574, 1984.
19. Antai-Otong D: The art of prescribing. Principles of switching novel antipsychotic medications. Perspectives in Psychiatric Care 41:45-47, 2005.
20. Casey DE, Carson WH, Saha AR, et al: Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166:391-399, 2003.
21. Weiden PJ, Simpson GM, Potkin SG, et al: Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. Journal of Clinical Psychiatry 64:580-588, 2003.
22. Simpson GM, Glick ID, Weiden PJ, et al: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. American Journal of Psychiatry 161:1837-1847, 2004.
23. Leslie DL, Rosenheck RA: From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. American Journal of Psychiatry 159:1534-1540, 2002.
24. Rothbard AB, Kuno E, Foley K: Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bulletin 29:531-540, 2003.
25. Hugenholtz GW, Heerdink ER, Meijer WE, et al: Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 38:122-124, 2005.
26. Ereshefsky L: Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. Journal of Clinical Psychiatry 60 (Suppl 10):20-30, 1999.
27. Tulloch KJ, Zed PJ: Intramuscular olanzapine in the management of acute agitation. The Annals of Pharmacotherapy 38:2128-2135, 2004.
28. Battaglia J: Pharmacological management of acute agitation. Drugs 65:1207-1222, 2005.
29. Johns CA, Thompson JW: Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophrenia Bulletin 21:607-619, 1995.
30. Voirol P, Robert PA, Meister P, et al: Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 32:29-37, 1999.